



Contact: Rehab AlJamal-Naylor
Tel. 017919-621 733
Email: r.aljamal.naylor@avipero.com

FOR IMMEDIATE RELEASE

Tuesday, 20 October 2015

**AVIPERO and United States Army Medical Research Institute of Infectious Diseases
Announce Positive results of Collaboration**

EDINBURGH, SCOTLAND- 20 October 2015-----AVIPERO (Registered in Scotland SC353945) announced today the first successful results from the Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) on anti-infectives.

Under the collaboration, USAMRIID and Avipero jointly established a research program focused on emerging viral infections.

The results showed positive anti-viral activity of a novel therapeutic strategy against Ebola by targeting host mechanisms utilised by the Ebola virus. The strategy entailed a combination of an antibody against the cell adhesion receptor, beta1 integrin, and a derivative of the marketed cholesterol-lowering drug ezetimibe. The treatment combination demonstrated synergistic mode of action reducing viremia by 80% in cell culture models. The treatment showed no toxicity.

“The collaboration marks the start of the expansion of Avipero’s platform aimed at providing tangible outcomes for the treatment of emerging viral infections of high unmet medical need” Avipero’s Chief Scientific Officer remarked.

About AVIPERO Ltd.

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson’s disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.

About United States Army Medical Research Institute of Infectious Diseases

USAMRIID’s mission is to provide leading edge medical capabilities to deter and defend against current and emerging biological threat agents. Research conducted at USAMRIID leads to medical solutions—vaccines, drugs, diagnostics, and information—that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency’s Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects”, and similar expressions. While forward-looking statements represent management’s outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such

factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Rehab AlJamal-Naylor
AVIPERO Ltd
Director and CSO,
+44(0)7919-621-733
info@avipero.com
www.avipero.com